| Literature DB >> 16750231 |
J Berman1, A D M Bryceson, S Croft, J Engel, W Gutteridge, J Karbwang, H Sindermann, J Soto, S Sundar, J A Urbina.
Abstract
Future issues that need to be addressed for miltefosine are efficacy against non-Indian visceral leishmaniasis, efficacy in HIV-coinfected patients, efficacy against the many forms of cutaneous and mucosal disease, effectiveness under clinical practice conditions, generation of drug resistance and the need to provide a second antileishmanial agent to protect against this disastrous event, and the ability to maintain reproductive contraceptive practices under routine clinical conditions.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16750231 DOI： 10.1016/j.trstmh.2006.02.009
Source DB: PubMed Journal: Trans R Soc Trop Med Hyg ISSN： 0035-9203 Impact factor: 2.184